Inforlife Company Profile
What is the competitive landscape for INFORLIFE
INFORLIFE has eleven approved drugs.
There are four US patents protecting INFORLIFE drugs.
Summary for Inforlife
| US Patents: | 4 |
| Tradenames: | 11 |
| Ingredients: | 10 |
| NDAs: | 11 |
| Patent Litigation for Inforlife: | See patent lawsuits for Inforlife |
Drugs and US Patents for Inforlife
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inforlife | NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | norepinephrine bitartrate | SOLUTION;INTRAVENOUS | 215700-004 | Oct 15, 2025 | RX | Yes | Yes | RE49443 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Inforlife | NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | norepinephrine bitartrate | SOLUTION;INTRAVENOUS | 215700-001 | Sep 15, 2022 | RX | Yes | Yes | 10,888,534 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Inforlife | ZOLEDRONIC ACID | zoledronic acid | INJECTABLE;INTRAVENOUS | 203231-001 | Aug 2, 2013 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Inforlife | ZOLEDRONIC ACID | zoledronic acid | INJECTABLE;INTRAVENOUS | 202828-001 | Sep 23, 2013 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Inforlife | NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE | nicardipine hydrochloride | INJECTABLE;INTRAVENOUS | 203978-001 | Apr 17, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Inforlife Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Moldova, Republic of | 20160103 | ⤷ Start Trial |
| Uruguay | 35988 | ⤷ Start Trial |
| Montenegro | 03004 | ⤷ Start Trial |
| Japan | 6635927 | ⤷ Start Trial |
| Spain | 2663817 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Inforlife Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1429780 | SPC/GB12/058 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 |
| 1429780 | 122012000070 | Germany | ⤷ Start Trial | PRODUCT NAME: KOMBINATION AUS CIPROFLOXACIN UND DEXAMETHASON, INSBESONDERE CIPROFLOXACINHYDROCHLORID UND DEXAMETHASON; NAT. REGISTRATION NO/DATE: 85150.00. 00 20120830; FIRST REGISTRATION: DAENEMARK 48976 20120808 |
| 1429780 | 13C0012 | France | ⤷ Start Trial | PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808 |
| 0328535 | 96C0021 | Belgium | ⤷ Start Trial | PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209 |
| 0258618 | SPC/GB01/042 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: ZOLEDRONIC ACID 2-(IMIDAZOL-1-YL)-1-HYDROXYETHANE-1,1-DIPHOSPHONIC ACID; REGISTERED: CH 55463 20001128; UK EU/1/01/176/001 20010320; UK EU/1/01/176/002 20010320; UK EU/1/01/176/003 20010320 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
